Polskie Archiwum Medycyny Wewnętrznej · 2013 · 17 citations · 19 references
MedicineCardiologyToxicologyEnvironmental HealthPreventive CardiologyTobacco ControlCardiovascular DiseaseCardiovascular Disease PreventionCoronary Artery DiseaseIschemic Heart DiseaseTobacco CessationTobacco UseCardiovascular Risk Reduction Through Smoking CessationCigarette Smoking PrevalenceSmoking-related Cardiac RiskTobacco Smoke ExposureTobacco Smoke ToxicologyTobacco SmokingVapor Phase ToxicityVascular Endothelial Dysfunction
INTRODUCTION: Exposure to tobacco smoke is associated with a higher cardiovascular risk, especially in patients with coronary artery disease (CAD). OBJECTIVES: The aim of the study was to evaluate the effect of active and passive tobacco smoking on the activity of endothelial markers in advanced atherosclerosis. PATIENTS AND METHODS: We studied 181 consecutive patients with advanced CAD (53 women and 128 men) aged 60 ±8 years, including 102 active self‑declared smokers (56.3%). We determined plasma asymmetric dimethylarginine (ADMA), thrombomodulin (TM), and plasminogen activator inhibitor‑1 (PAI‑1) levels, along with serum cotinine concentrations as a marker of tobacco smoking. RESULTS: Plasma ADMA levels were higher in active smokers compared with nonsmokers (0.60 ±0.09 μmol/l vs. 0.49 ±0.08 μmol/l, P <0.001). There were similar intergroup differences in TM (4.60 ±2.11 ng/ml vs. 3.0 ±1.7 ng/ml, P <0.0001) and PAI‑1 levels (30.3 ±12.4 ng/ml vs. 23.6 ±11.3 ng/ml, P <0.0001). We observed positive correlations between cotinine and ADMA (r = 0.71, P <0.0001), TM (r = 0.53, P <0.0001), and PAI‑1 (r = 0.58, P <0.0001). In 21 patients (26.6%) who declared to be nonsmokers, cotinine levels (mean, 6.30 ±22.5 ng/ml) significantly correlated with ADMA, TM, and PAI‑1 (all P <0.001). A multivariate regression analysis showed that cotinine was an independent predictor of ADMA, TM, and PAI‑1 in the whole patient group. CONCLUSIONS: Despite long‑lasting endothelial injury in advanced CAD, continued cigarette smoking is able to further enhance endothelial damage by increasing ADMA levels and resultant inhibition of fibrinolysis.
19
Neal L. Benowitz, John T. Bernert, Ralph S. Caraballo et al. · American Journal of Epidemiology · 2008 · 667 citations · Full text
Public Health, Population Health Sciences, Clinical Epidemiology +13
Tom Teerlink, Robert J. Nijveldt, Sigrid de Jong et al. · Analytical Biochemistry · 2002 · 421 citations
Pharmacy, Pharmaceutical Analysis, Chromatographic Analysis +5
Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease
Jun Wang, Ah Siew Sim, Xing Li Wang et al. · Atherosclerosis · 2005 · 95 citations
Medicine, Cardiology, Pharmacology +16